Clinical trials: GastroEsophageal Junction (GEJ) Cancer
Advanced Cancer, Advanced Malignancies
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
- Conditions
- Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer
- Trial name
- ARC-25 (NCT05891171)
- Testing
- AB598, Zimberelimab, Fluorouracil
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 40 people
- Sponsor
- Arcus Biosciences, Inc.
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
This phase II MATCH treatment trial identifies the effects of ado-trastuzumab emtansine in patients whose cancer has a genetic change called HER2 amplification.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439110
- Testing
- Trastuzumab Emtansine
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer, Cancer of Stomach
A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)
This is a Phase 2, signal generating, open-label, 2-Arm, non-randomized study, in patients with metastatic HER2/neu over-expressing gastric cancer or gastroesophageal adenocarcinomas.
- Conditions
- Gastric Cancer, Cancer of Stomach, Gastric Adenocarcinoma, Stomach Cancer
- Trial name
- nextHERIZON (NCT05311176)
- Testing
- IMU-131, Ramucirumab plus Paclitaxel, Pembrolizumab
- Where
- 7 sites in Australia, Taiwan
- Volunteers
- 7 people
- Sponsor
- Imugene Limited
Gastric Cancer, Gastroesophageal Junction (GEJ) Adenocarcinoma
Becotatugvedotin Plus Pucotenlimab in EGFR-Positive Advanced Gastric/GEJ Adenocarcinoma
Advanced gastric cancer (AGC) and gastroesophageal junction (GEJ) adenocarcinoma remain associated with poor prognosis after failure of first-line systemic therapy.
- Conditions
- Gastric Cancer, Gastroesophageal Junction (GEJ) Adenocarcinoma, Becotatug Vedotin, Pucotenlimab
- Trial name
- NCT07692334
- Testing
- Becotatug Vedotin (MRG003), Pucotenlimab
- Volunteers
- 28 people
- Sponsor
- West China Second University Hospital
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
This is a multicenter, global, Phase 2, open-label, 2-part, first-line study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) plus standard first-line combination chemotherapy regimens for…
- Trial name
- NCT03929666
- Testing
- ZW25 (Zanidatamab), Capecitabine, Cisplatin
- Where
- 23 sites in United States, Canada and 2 more
- Volunteers
- 74 people
- Sponsor
- Jazz Pharmaceuticals
Breast Cancer, Gastric Cancer
IKS014 in Advanced Solid Tumors That Express HER2
This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate…
- Conditions
- Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
- Trial name
- NCT05872295
- Testing
- IKS014
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 165 people
- Sponsor
- Iksuda Therapeutics Ltd.
Gastric Cancer (GC), Peritoneal Metastases From Gastric Cancer
Retlirafusp Alfa Plus SOX and Intraperitoneal Nab-Paclitaxel for Advanced Gastric/GEJ Cancer With Malignant Ascites
To evaluate the efficacy and safety of retlirafusp alfa in combination with SOX chemotherapy and intraperitoneal nab-paclitaxel as first-line treatment for advanced gastric/gastroesophageal junction (GC/GEJ) adenocarcinoma with…
- Conditions
- Gastric Cancer (GC), Peritoneal Metastases From Gastric Cancer, Ascites, Malignant
- Trial name
- NCT07855757
- Testing
- Retlirafusp Alfa + SOX + Intraperitoneal Nab-Paclitaxel
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors.
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT05365581
- Testing
- ASP2138, Pembrolizumab, Oxaliplatin
- Where
- 46 sites in United States, China and 6 more
- Volunteers
- 398 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Adenocarcinoma Gastric Stage IV With Metastases, Adenocarcinoma - GEJ
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
This study will find out if trastuzumab deruxtecan is safe and works for participants with gastric or gastroesophageal junction cancer.
- Trial name
- NCT04014075
- Testing
- Trastuzumab deruxtecan
- Where
- 37 sites in United States, Belgium and 3 more
- Volunteers
- 79 people
- Sponsor
- Daiichi Sankyo
Gastric Cancer, Gastroesophageal-junction Cancer
A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer
The purpose of this study is to find out whether adding cadonilimab to the usual chemotherapy approach is an effective and safe treatment for participants with locally advanced/resectable gastric cancer or gastroesophageal…
- Trial name
- NCT07631000
- Testing
- Cadonilimab
- Where
- 7 sites in United States
- Volunteers
- 37 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Gastric Adenocarcinoma
First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC
In this clinical study, investigators explore the efficacy and safety of a combination therapy regimen with antiangiogenic agent (apatinib), ICI (tislelizumab), and chemotherapy (capecitabine+ Oxaliplatin, XELOX) as first-line…
- Trial name
- RENMIN-213 (NCT06238752)
- Testing
- Apatinib Combined With Tislelizumab and Chemotherapy
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Renmin Hospital of Wuhan University
Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma
Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer
Multi-center, open-label, non-randomized Phase II study to evaluate the efficacy and safety of OSI-7904L in gastric and GEJ cancers.
- Trial name
- NCT00073502
- Testing
- OSI-7904L
- Where
- 11 sites in United States, Belgium and 1 more
- Volunteers
- 43 people
- Sponsor
- OSI Pharmaceuticals
Stomach Neoplasms, Adenocarcinoma - Gastroesophageal Junction (GEJ)
The Efficacy and Safety of Laparoscopic Proximal Gastrectomy With LPG-tbROSF Versus LTG for Localized Proximal Gastric Cancer.
This clinical trial is evaluating a new, function-preserving surgical technique for patients with early-stage cancer in the upper part of the stomach.
- Conditions
- Stomach Neoplasms, Adenocarcinoma - Gastroesophageal Junction (GEJ), Gastroesophageal Junction Cancer
- Trial name
- NCT07260461
- Testing
- Laparoscopic Proximal Gastrectomy with Tubular Stomach-Based Right-Opening Single Flap Valvuloplasty (LPG-tbROSF)
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.
The goal of this clinical trial is to learn the efficaty and safety of BC001 in combination with Sintilimab and XELOX in treating patients with advanced or metastatic GC/GEJ.
- Trial name
- NCT06773312
- Testing
- BC001+Sintilimab+XELOX
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood.
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06131840
- Testing
- PF-08046050, bevacizumab, 5-Fluorouracil (5-FU)
- Where
- 48 sites in United States, Canada and 8 more
- Volunteers
- 914 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Gastro Esophageal Junction Cancer, Stomach Cancer
Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
To evaluate the antitumor activity and safety/tolerability of the combination (mFOLFOX + Pembrolizumab) in patients with potentially resectable adenocarcinoma of the Gastroesophageal Junction (GEJ) and stomach.
- Conditions
- Gastro Esophageal Junction Cancer, Stomach Cancer, Adenocarcinoma
- Trial name
- NCT03488667
- Testing
- Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab, Adjuvant Treatment - mFOLFOX & Pembrolizumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Kansas Medical Center
HER2-positive Gastric Cancer
Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma
A Phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel in patients with HER2-high and in combination with tucatanib in patients with HER2-low gastric or…
- Trial name
- NCT05190445
- Testing
- Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel, Cinrebafusp alfa (PRS-343) in combination with tucatinib
- Where
- 5 sites in United States, South Korea
- Volunteers
- 80 people
- Sponsor
- Pieris Pharmaceuticals, Inc.
ctDNA, Gastric Cancer
Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction Adenocarcinoma
This is a single-center, prospective, exploratory study evaluating the use of dynamic circulating tumor DNA (ctDNA) monitoring in the postoperative adjuvant treatment setting for patients with stage III or stage IVA gastric or…
- Conditions
- ctDNA, Gastric Cancer, Gastroesophageal Junction (GEJ) Adenocarcinoma, Adjuvant Treatment
- Trial name
- NCT07507916
- Testing
- HLX10, SOX Chemotherapy
- Volunteers
- 32 people
- Sponsor
- Fudan University
Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors.
- Conditions
- Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer
- Trial name
- NCT04895709
- Testing
- BMS-986340, BMS-936558-01, Docetaxel
- Where
- 47 sites in United States, Australia and 6 more
- Volunteers
- 1,109 people
- Sponsor
- Bristol-Myers Squibb
Gastric Cancer, Stomach Cancer
Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer
This study is to evaluate the efficacy and safety of addition of intraperitoneal (ip) Floxuridine to adjuvant chemoradiation therapy for patients under-going potentially curative stomach resection.
- Trial name
- NCT00858338
- Testing
- Potentially curative surgery, Floxuridine (IP), Adjuvant Chemoradiation therapy
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- NYU Langone Health